A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets.
Identifieur interne : 000B58 ( Ncbi/Curation ); précédent : 000B57; suivant : 000B59A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets.
Auteurs : Mariana Baz [États-Unis] ; Myeisha Paskel [États-Unis] ; Yumiko Matsuoka [États-Unis] ; James R. Zengel [États-Unis] ; Xing Cheng [États-Unis] ; John J. Treanor [États-Unis] ; Hong Jin [États-Unis] ; Kanta Subbarao [Indonésie]Source :
- Journal of virology [ 1098-5514 ] ; 2015.
Descripteurs français
- KwdFr :
- Adolescent, Adulte d'âge moyen, Animaux, Anticorps antiviraux (sang), Chiens, Femelle, Furets, Génétique inverse, Humains, Infections à Orthomyxoviridae (), Jeune adulte, Mâle, Recombinaison génétique, Souris de lignée BALB C, Sous-type H3N2 du virus de la grippe A (immunologie), Sous-type H3N8 du virus de la grippe A (immunologie), Sujet âgé, Sujet âgé de 80 ans ou plus, Vaccination (), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (génétique), Vaccins antigrippaux (immunologie), Vaccins antigrippaux (isolement et purification).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- génétique : Vaccins antigrippaux.
- immunologie : Sous-type H3N2 du virus de la grippe A, Sous-type H3N8 du virus de la grippe A, Vaccins antigrippaux.
- isolement et purification : Vaccins antigrippaux.
- sang : Anticorps antiviraux.
- Adolescent, Adulte d'âge moyen, Animaux, Chiens, Femelle, Furets, Génétique inverse, Humains, Infections à Orthomyxoviridae, Jeune adulte, Mâle, Recombinaison génétique, Souris de lignée BALB C, Sujet âgé, Sujet âgé de 80 ans ou plus, Vaccination.
English descriptors
- KwdEn :
- Adolescent, Aged, Aged, 80 and over, Animals, Antibodies, Viral (blood), Dogs, Female, Ferrets, Humans, Influenza A Virus, H3N2 Subtype (immunology), Influenza A Virus, H3N8 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (genetics), Influenza Vaccines (immunology), Influenza Vaccines (isolation & purification), Male, Mice, Inbred BALB C, Middle Aged, Orthomyxoviridae Infections (prevention & control), Recombination, Genetic, Reverse Genetics, Vaccination (methods), Young Adult.
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , blood : Antibodies, Viral.
- chemical , genetics : Influenza Vaccines.
- immunology : Influenza A Virus, H3N2 Subtype, Influenza A Virus, H3N8 Subtype, Influenza Vaccines.
- chemical , isolation & purification : Influenza Vaccines.
- methods : Vaccination.
- prevention & control : Orthomyxoviridae Infections.
- Adolescent, Aged, Aged, 80 and over, Animals, Dogs, Female, Ferrets, Humans, Male, Mice, Inbred BALB C, Middle Aged, Recombination, Genetic, Reverse Genetics, Young Adult.
Abstract
H3N8 influenza viruses are a commonly found subtype in wild birds, usually causing mild or no disease in infected birds. However, they have crossed the species barrier and have been associated with outbreaks in dogs, pigs, donkeys, and seals and therefore pose a threat to humans. A live attenuated, cold-adapted (ca) H3N8 vaccine virus was generated by reverse genetics using the wild-type (wt) hemagglutinin (HA) and neuraminidase (NA) genes from the A/blue-winged teal/Texas/Sg-00079/2007 (H3N8) (tl/TX/079/07) wt virus and the six internal protein gene segments from the ca influenza A virus vaccine donor strain, A/Ann Arbor/6/60 ca (H2N2), the backbone of the licensed seasonal live attenuated influenza vaccine. One dose of the tl/TX/079/07 ca vaccine induced a robust neutralizing antibody response against the homologous (tl/TX/079/07) and two heterologous influenza viruses, including the recently emerged A/harbor seal/New Hampshire/179629/2011 (H3N8) and A/northern pintail/Alaska/44228-129/2006 (H3N8) viruses, and conferred robust protection against the homologous and heterologous influenza viruses. We also analyzed human sera against the tl/TX/079/07 H3N8 avian influenza virus and observed low but detectable antibody reactivity in elderly subjects, suggesting that older H3N2 influenza viruses confer some cross-reactive antibody. The latter observation was confirmed in a ferret study. The safety, immunogenicity, and efficacy of the tl/TX/079/07 ca vaccine in mice and ferrets support further evaluation of this vaccine in humans for use in the event of transmission of an H3N8 avian influenza virus to humans. The human and ferret serology data suggest that a single dose of the vaccine may be sufficient in older subjects.
DOI: 10.1128/JVI.00280-15
PubMed: 25903333
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000076
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000076
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000083
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000B58
Links to Exploration step
pubmed:25903333Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets.</title>
<author><name sortKey="Baz, Mariana" sort="Baz, Mariana" uniqKey="Baz M" first="Mariana" last="Baz">Mariana Baz</name>
<affiliation wicri:level="2"><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Paskel, Myeisha" sort="Paskel, Myeisha" uniqKey="Paskel M" first="Myeisha" last="Paskel">Myeisha Paskel</name>
<affiliation wicri:level="2"><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Matsuoka, Yumiko" sort="Matsuoka, Yumiko" uniqKey="Matsuoka Y" first="Yumiko" last="Matsuoka">Yumiko Matsuoka</name>
<affiliation wicri:level="2"><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zengel, James R" sort="Zengel, James R" uniqKey="Zengel J" first="James R" last="Zengel">James R. Zengel</name>
<affiliation wicri:level="2"><nlm:affiliation>MedImmune LLC, Mountain View, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>MedImmune LLC, Mountain View, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cheng, Xing" sort="Cheng, Xing" uniqKey="Cheng X" first="Xing" last="Cheng">Xing Cheng</name>
<affiliation wicri:level="2"><nlm:affiliation>MedImmune LLC, Mountain View, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>MedImmune LLC, Mountain View, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Treanor, John J" sort="Treanor, John J" uniqKey="Treanor J" first="John J" last="Treanor">John J. Treanor</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of Rochester Medical Center, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jin, Hong" sort="Jin, Hong" uniqKey="Jin H" first="Hong" last="Jin">Hong Jin</name>
<affiliation wicri:level="2"><nlm:affiliation>MedImmune LLC, Mountain View, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>MedImmune LLC, Mountain View, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
<affiliation wicri:level="1"><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA ksubbarao@niaid.nih.gov.</nlm:affiliation>
<country wicri:rule="url">Indonésie</country>
<wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland</wicri:regionArea>
<wicri:noRegion>Maryland</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25903333</idno>
<idno type="pmid">25903333</idno>
<idno type="doi">10.1128/JVI.00280-15</idno>
<idno type="wicri:Area/PubMed/Corpus">000076</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000076</idno>
<idno type="wicri:Area/PubMed/Curation">000076</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000076</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000083</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000083</idno>
<idno type="wicri:Area/Ncbi/Merge">000B58</idno>
<idno type="wicri:Area/Ncbi/Curation">000B58</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets.</title>
<author><name sortKey="Baz, Mariana" sort="Baz, Mariana" uniqKey="Baz M" first="Mariana" last="Baz">Mariana Baz</name>
<affiliation wicri:level="2"><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Paskel, Myeisha" sort="Paskel, Myeisha" uniqKey="Paskel M" first="Myeisha" last="Paskel">Myeisha Paskel</name>
<affiliation wicri:level="2"><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Matsuoka, Yumiko" sort="Matsuoka, Yumiko" uniqKey="Matsuoka Y" first="Yumiko" last="Matsuoka">Yumiko Matsuoka</name>
<affiliation wicri:level="2"><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zengel, James R" sort="Zengel, James R" uniqKey="Zengel J" first="James R" last="Zengel">James R. Zengel</name>
<affiliation wicri:level="2"><nlm:affiliation>MedImmune LLC, Mountain View, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>MedImmune LLC, Mountain View, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cheng, Xing" sort="Cheng, Xing" uniqKey="Cheng X" first="Xing" last="Cheng">Xing Cheng</name>
<affiliation wicri:level="2"><nlm:affiliation>MedImmune LLC, Mountain View, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>MedImmune LLC, Mountain View, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Treanor, John J" sort="Treanor, John J" uniqKey="Treanor J" first="John J" last="Treanor">John J. Treanor</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of Rochester Medical Center, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jin, Hong" sort="Jin, Hong" uniqKey="Jin H" first="Hong" last="Jin">Hong Jin</name>
<affiliation wicri:level="2"><nlm:affiliation>MedImmune LLC, Mountain View, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>MedImmune LLC, Mountain View, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
<affiliation wicri:level="1"><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA ksubbarao@niaid.nih.gov.</nlm:affiliation>
<country wicri:rule="url">Indonésie</country>
<wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland</wicri:regionArea>
<wicri:noRegion>Maryland</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of virology</title>
<idno type="eISSN">1098-5514</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Animals</term>
<term>Antibodies, Viral (blood)</term>
<term>Dogs</term>
<term>Female</term>
<term>Ferrets</term>
<term>Humans</term>
<term>Influenza A Virus, H3N2 Subtype (immunology)</term>
<term>Influenza A Virus, H3N8 Subtype (immunology)</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (genetics)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza Vaccines (isolation & purification)</term>
<term>Male</term>
<term>Mice, Inbred BALB C</term>
<term>Middle Aged</term>
<term>Orthomyxoviridae Infections (prevention & control)</term>
<term>Recombination, Genetic</term>
<term>Reverse Genetics</term>
<term>Vaccination (methods)</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Adulte d'âge moyen</term>
<term>Animaux</term>
<term>Anticorps antiviraux (sang)</term>
<term>Chiens</term>
<term>Femelle</term>
<term>Furets</term>
<term>Génétique inverse</term>
<term>Humains</term>
<term>Infections à Orthomyxoviridae ()</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Recombinaison génétique</term>
<term>Souris de lignée BALB C</term>
<term>Sous-type H3N2 du virus de la grippe A (immunologie)</term>
<term>Sous-type H3N8 du virus de la grippe A (immunologie)</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Vaccination ()</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Vaccins antigrippaux (génétique)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins antigrippaux (isolement et purification)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H3N2 du virus de la grippe A</term>
<term>Sous-type H3N8 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H3N2 Subtype</term>
<term>Influenza A Virus, H3N8 Subtype</term>
<term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Vaccination</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Animals</term>
<term>Dogs</term>
<term>Female</term>
<term>Ferrets</term>
<term>Humans</term>
<term>Male</term>
<term>Mice, Inbred BALB C</term>
<term>Middle Aged</term>
<term>Recombination, Genetic</term>
<term>Reverse Genetics</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte d'âge moyen</term>
<term>Animaux</term>
<term>Chiens</term>
<term>Femelle</term>
<term>Furets</term>
<term>Génétique inverse</term>
<term>Humains</term>
<term>Infections à Orthomyxoviridae</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Recombinaison génétique</term>
<term>Souris de lignée BALB C</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Vaccination</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">H3N8 influenza viruses are a commonly found subtype in wild birds, usually causing mild or no disease in infected birds. However, they have crossed the species barrier and have been associated with outbreaks in dogs, pigs, donkeys, and seals and therefore pose a threat to humans. A live attenuated, cold-adapted (ca) H3N8 vaccine virus was generated by reverse genetics using the wild-type (wt) hemagglutinin (HA) and neuraminidase (NA) genes from the A/blue-winged teal/Texas/Sg-00079/2007 (H3N8) (tl/TX/079/07) wt virus and the six internal protein gene segments from the ca influenza A virus vaccine donor strain, A/Ann Arbor/6/60 ca (H2N2), the backbone of the licensed seasonal live attenuated influenza vaccine. One dose of the tl/TX/079/07 ca vaccine induced a robust neutralizing antibody response against the homologous (tl/TX/079/07) and two heterologous influenza viruses, including the recently emerged A/harbor seal/New Hampshire/179629/2011 (H3N8) and A/northern pintail/Alaska/44228-129/2006 (H3N8) viruses, and conferred robust protection against the homologous and heterologous influenza viruses. We also analyzed human sera against the tl/TX/079/07 H3N8 avian influenza virus and observed low but detectable antibody reactivity in elderly subjects, suggesting that older H3N2 influenza viruses confer some cross-reactive antibody. The latter observation was confirmed in a ferret study. The safety, immunogenicity, and efficacy of the tl/TX/079/07 ca vaccine in mice and ferrets support further evaluation of this vaccine in humans for use in the event of transmission of an H3N8 avian influenza virus to humans. The human and ferret serology data suggest that a single dose of the vaccine may be sufficient in older subjects.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B58 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000B58 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= H2N2V1 |flux= Ncbi |étape= Curation |type= RBID |clé= pubmed:25903333 |texte= A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:25903333" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a H2N2V1
This area was generated with Dilib version V0.6.33. |